Her pharmacist said 'that's just what it costs.' It wasn't.
Jennifer, 48, was diagnosed with rheumatoid arthritis two years ago. Her doctor prescribed Humira — a biologic injection that had become the standard of care for her condition. She picked it up at the pharmacy: $340 per month, even with insurance.
Her plan had high cost-sharing for specialty drugs. Her pharmacist shrugged. "That's just what biologics cost." Jennifer went home and started quietly budgeting around it.
"I need this medication. My doctor prescribed it. My insurance covers it, sort of. Is there any alternative, or do I just pay $4,080 a year forever?"
Jennifer had never heard the word "biosimilar." She assumed brand-name biologics had no generic equivalent.
FDA-approved biosimilars are the biological equivalent of generic drugs — different manufacturer, same active ingredient, same clinical effect, dramatically lower price. As of 2024, Humira has more than a dozen FDA-approved biosimilars including Hadlima, Cyltezo, and Hyrimoz, priced 70-85% lower.
Beyond biosimilars, most major drug manufacturers run Patient Assistance Programs for income-qualified patients that can reduce costs to zero. And prescription discount apps like GoodRx or Cost Plus can sometimes beat even insurance pricing for generics.
$340/month became $35/month. Jennifer saves $3,660 every year — for the same therapeutic effect, from an FDA-approved medication her own doctor approved. It took one conversation and one new prescription.